Tim has more than 30 years global large and small Pharma experience in Target Identification, Drug Discovery and Development. Before setting up DeuterOncology, Tim was the Founder and CSO of OCTIMET oncology NV. Prior to that Tim was the Global Discovery Leader for the Lung Disease Area at J&J. Tim was recognized for the quality of the research and dedication to Janssen R&D by being made a Janssen Research Fellow in 2012. During his career at JNJ he led multiple discovery projects teams including 4 that reached the clinic. Tim was the Discovery Project Leader and Project Champion for the first globally approved FGFR kinase inhibitor Balversa (erdafitinib).
Tim was responsible for the initial idea for the use of deuteration as a means to modulate metabolic properties of the parent drug and remains a strong champion for this exciting new molecule. Tim is a named inventor on 13 published patents and coauthor on more than 30 scientific publications.